Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy

Arihiko Kanaji, Masaaki Higashi, Masako Namisato, Makoto Nishio, Kenichi Ando, Harumoto Yamada

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients. The purpose of the present study was to evaluate the therapeutic effect on oral administration of risedronate in male osteoporotic patients with leprosy. Twenty-three male patients with leprosy, 63-87 years of age, were randomly divided into two administration groups: R group (risedronate, 2.5 mg/day, daily) and P group (placebo, daily). The BMD of the lumbar spine (L2-L4) was measured by dual-energy X-ray absorptiometry, and urinary cross linked N-telopeptides of type I collagen (NTX) were assessed at baseline, 6 months, and 12 months after treatment. There were no significant differences in age, body mass index, BMD, or urinary NTX levels at baseline between the two groups. In the present study, oral administration of risedronate apparently prevented vertebral fractures by increasing lumbar BMD and caused a significant reduction in urinary NTX levels, while oral administration of placebo did not increase the lumbar BMD and prevent vertebral fractures due to osteoporosis. The above findings suggested that oral administration of risedronate contributed to the prevention of vertebral fractures by suppressing bone resorption and increasing in lumbar BMD in the elderly male patients with leprosy.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalLeprosy Review
Volume77
Issue number2
Publication statusPublished - 24-07-2006

Fingerprint

Leprosy
Bone Resorption
Bone Density
Oral Administration
Incidence
Osteoporosis
Placebos
Bone Fractures
Photon Absorptiometry
Therapeutic Uses
Collagen Type I
Risedronate Sodium
Spine
Body Mass Index
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kanaji, Arihiko ; Higashi, Masaaki ; Namisato, Masako ; Nishio, Makoto ; Ando, Kenichi ; Yamada, Harumoto. / Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. In: Leprosy Review. 2006 ; Vol. 77, No. 2. pp. 147-153.
@article{aed2425610714dce88f8b9836112045c,
title = "Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy",
abstract = "There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients. The purpose of the present study was to evaluate the therapeutic effect on oral administration of risedronate in male osteoporotic patients with leprosy. Twenty-three male patients with leprosy, 63-87 years of age, were randomly divided into two administration groups: R group (risedronate, 2.5 mg/day, daily) and P group (placebo, daily). The BMD of the lumbar spine (L2-L4) was measured by dual-energy X-ray absorptiometry, and urinary cross linked N-telopeptides of type I collagen (NTX) were assessed at baseline, 6 months, and 12 months after treatment. There were no significant differences in age, body mass index, BMD, or urinary NTX levels at baseline between the two groups. In the present study, oral administration of risedronate apparently prevented vertebral fractures by increasing lumbar BMD and caused a significant reduction in urinary NTX levels, while oral administration of placebo did not increase the lumbar BMD and prevent vertebral fractures due to osteoporosis. The above findings suggested that oral administration of risedronate contributed to the prevention of vertebral fractures by suppressing bone resorption and increasing in lumbar BMD in the elderly male patients with leprosy.",
author = "Arihiko Kanaji and Masaaki Higashi and Masako Namisato and Makoto Nishio and Kenichi Ando and Harumoto Yamada",
year = "2006",
month = "7",
day = "24",
language = "English",
volume = "77",
pages = "147--153",
journal = "Leprosy Review",
issn = "0305-7518",
publisher = "British Leprosy Relief Association",
number = "2",

}

Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. / Kanaji, Arihiko; Higashi, Masaaki; Namisato, Masako; Nishio, Makoto; Ando, Kenichi; Yamada, Harumoto.

In: Leprosy Review, Vol. 77, No. 2, 24.07.2006, p. 147-153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy

AU - Kanaji, Arihiko

AU - Higashi, Masaaki

AU - Namisato, Masako

AU - Nishio, Makoto

AU - Ando, Kenichi

AU - Yamada, Harumoto

PY - 2006/7/24

Y1 - 2006/7/24

N2 - There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients. The purpose of the present study was to evaluate the therapeutic effect on oral administration of risedronate in male osteoporotic patients with leprosy. Twenty-three male patients with leprosy, 63-87 years of age, were randomly divided into two administration groups: R group (risedronate, 2.5 mg/day, daily) and P group (placebo, daily). The BMD of the lumbar spine (L2-L4) was measured by dual-energy X-ray absorptiometry, and urinary cross linked N-telopeptides of type I collagen (NTX) were assessed at baseline, 6 months, and 12 months after treatment. There were no significant differences in age, body mass index, BMD, or urinary NTX levels at baseline between the two groups. In the present study, oral administration of risedronate apparently prevented vertebral fractures by increasing lumbar BMD and caused a significant reduction in urinary NTX levels, while oral administration of placebo did not increase the lumbar BMD and prevent vertebral fractures due to osteoporosis. The above findings suggested that oral administration of risedronate contributed to the prevention of vertebral fractures by suppressing bone resorption and increasing in lumbar BMD in the elderly male patients with leprosy.

AB - There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients. The purpose of the present study was to evaluate the therapeutic effect on oral administration of risedronate in male osteoporotic patients with leprosy. Twenty-three male patients with leprosy, 63-87 years of age, were randomly divided into two administration groups: R group (risedronate, 2.5 mg/day, daily) and P group (placebo, daily). The BMD of the lumbar spine (L2-L4) was measured by dual-energy X-ray absorptiometry, and urinary cross linked N-telopeptides of type I collagen (NTX) were assessed at baseline, 6 months, and 12 months after treatment. There were no significant differences in age, body mass index, BMD, or urinary NTX levels at baseline between the two groups. In the present study, oral administration of risedronate apparently prevented vertebral fractures by increasing lumbar BMD and caused a significant reduction in urinary NTX levels, while oral administration of placebo did not increase the lumbar BMD and prevent vertebral fractures due to osteoporosis. The above findings suggested that oral administration of risedronate contributed to the prevention of vertebral fractures by suppressing bone resorption and increasing in lumbar BMD in the elderly male patients with leprosy.

UR - http://www.scopus.com/inward/record.url?scp=33746035631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746035631&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 147

EP - 153

JO - Leprosy Review

JF - Leprosy Review

SN - 0305-7518

IS - 2

ER -